Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$17,500.00
A novel immunotherapy for Rheumatoid Arthritis: targeting citrullinated epitope-specific T cells
EF 2021-22
Résumé
Rheumatoid arthritis (RA) is a chronic, autoimmune disease that primarily affects the joints of the hands, knees, and feet of about 1 in every 100 individuals. In RA, the bodys immune system mistakenly attacks its tissues and damages the bone and cartilage that comprise the joint space, leading to deformities and stiffness. Patients diagnosed with this debilitating disease experience decreased quality of life and engagement in daily activities due to mobility restraints. Currently, the treatments of RA incur significant costs totalling over $5.7 billion annually, and there is a high risk of patients having adverse events, along with clinical remission (disease-free) rates being low (less than 10%). In addition, RA poses a growing concern as there are no curative treatment options available, and the number of individuals affected by the disease will increase as the total population ages. Thus, this project aims to develop a novel, DNA-based vaccine therapy that can reduce existing RA symptoms by first testing in human liver and muscle cells and then within humanized mouse models that resemble RA. By injecting into cells or mice, our treatment contains the genetic information to produce the fragments of proteins that are commonly targeted by the immune system in RA patients. In effect, this technique will aim to solely turn off the joint-attacking cells specific to the RA proteins and not other components of the immune system used to protect against invaders, which should decrease the swelling and inflammation of the joints. By proving the concept of the DNA vaccine in animal models, we believe our approach will steer further innovations in combating autoimmune diseases and potentially provide a life-improving therapy.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
467216
Name
Malhotra Devon
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
A novel immunotherapy for Rheumatoid Arthritis: targeting citrullinated epitope-specific T cells
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adeno-Associated Viruses; Anti-Citrullinated Protein Antibodies; Citrullination; Human Leukocyte Antigen; Immunological Tolerance; Inflammation/Auto-Immune; Peptide Immunotherapy; Peptidylarginine Deiminases; Rheumatoid Arthritis; Shared Epitope
Abstract
Rheumatoid arthritis (RA) is a chronic, autoimmune disease that primarily affects the joints of the hands, knees, and feet of about 1 in every 100 individuals. In RA, the bodys immune system mistakenly attacks its tissues and damages the bone and cartilage that comprise the joint space, leading to deformities and stiffness. Patients diagnosed with this debilitating disease experience decreased quality of life and engagement in daily activities due to mobility restraints. Currently, the treatments of RA incur significant costs totalling over $5.7 billion annually, and there is a high risk of patients having adverse events, along with clinical remission (disease-free) rates being low (less than 10%). In addition, RA poses a growing concern as there are no curative treatment options available, and the number of individuals affected by the disease will increase as the total population ages. Thus, this project aims to develop a novel, DNA-based vaccine therapy that can reduce existing RA symptoms by first testing in human liver and muscle cells and then within humanized mouse models that resemble RA. By injecting into cells or mice, our treatment contains the genetic information to produce the fragments of proteins that are commonly targeted by the immune system in RA patients. In effect, this technique will aim to solely turn off the joint-attacking cells specific to the RA proteins and not other components of the immune system used to protect against invaders, which should decrease the swelling and inflammation of the joints. By proving the concept of the DNA vaccine in animal models, we believe our approach will steer further innovations in combating autoimmune diseases and potentially provide a life-improving therapy.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Malhotra, Devon
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~